Beneficial Effects of Triacetyl Azauridine in Psoriasis and Mycosis Fungoides
Authors: PAUL CALABRESI
Journal: Annals of Internal Medicine (1966)

Article1 February 1966Beneficial Effects of Triacetyl Azauridine in Psoriasis and Mycosis FungoidesPAUL CALABRESI, M.D., RAYMOND W. TURNER, M.D.PAUL CALABRESI, M.D.Search for more papers by this author, RAYMOND W. TURNER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-64-2-352 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe usefulness of antimetabolites capable of inhibiting nucleic acid biosynthesis has been generally limited by their severe systemic toxicity. Although beneficial effects have been observed in certain neoplastic disorders, the ability of these compounds to inhibit proliferation of all rapidly reproducing tissues often results in marked hematopoietic suppression, stomatitis, gastrointestinal ulcerations, and loss of hair (1). Increased mitotic activity and hyperplasia are also characteristics of the epidermal lesion of psoriasis. Interference with cellular replication by antimetabolites and related antineoplastic agents has achieved beneficial results in psoriasis but not without toxic manifestations due to similar effects in the normal tissues of...References1. CALABRESIWELCH PAD: Chemotherapy of neoplastic diseases. Ann. Rev. Med. 13: 147, 1962. Also in The Pharmacological Basis of Therapeutics, 3rd ed., Section XV, by GOODMAN and GILMAN. The Macmillian Co., New York, 1965, p. 1343. CrossrefMedlineGoogle Scholar2. VAN SCOTTREINERTSON EJRP: Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J. Invest. Derm. 33: 357, 1959. CrossrefMedlineGoogle Scholar3. CALABRESI P: Current status of clinical investigations with 6-azauridine, 5-iodo-2′-deoxyuridine and related derivatives. Cancer Res. 23: 1260, 1963. MedlineGoogle Scholar4. HANDSCHUMACHERCALABRESIWELCHBONOFALLONFREI REPADVHE: Summary of current information on 6-azauridine. Cancer Chemother. Rep. 21: 1, 1962. MedlineGoogle Scholar5. CARDOSOCALABRESIHANDSCHUMACHER SSPRE: Alterations in human pyrimidine metabolism as a result of therapy with 6-azauridine. Cancer Res. 21: 1551, 1961. MedlineGoogle Scholar6. PASTERNAKHANDSCHUMACHER CARE: The biochemical action of AzUR: Interference with pyrimidine metabolism in transplanted mouse tumors. J. Biol. Chem. 234: 2992, 1959. CrossrefMedlineGoogle Scholar7. SCHNIDERFREIRUOHYGORMANFREIREICHBRINDLEYCLEMENTS BIEJHJEJCOJ: Clinical studies of 6-azauracil. Cancer Res. 20: 29, 1960. Google Scholar8. WELCHHANDSCHUMACHERFINCHJAFFECARDOSOCALABRESI ADRESCJJSSP: A synopsis of recent investigations of 6-azauridine (NSC-32074). Cancer Chemother. Rep. 9: 39, 1960. MedlineGoogle Scholar9. CREASEYFINKHANDSCHUMACHERCALABRESI WAMEREP: Clinical and pharmacological studies with 2′,3′, 5-triacetyl-6-azauridine. Cancer Res. 23: 444, 1963. MedlineGoogle Scholar10. CALABRESITURNERLEFKOWITZ PRER: Beneficial effects of azauridine in psoriasis and mycosis fungoides. Proc. Amer. Ass. Cancer Res. 5: 10, 1964. Google Scholar11. TURNERCALABRESI RP: The effect of triacetyl AzUR on psoriasis. J. Invest. Derm. 43: 551, 1964. CrossrefMedlineGoogle Scholar12. SUTTONSUTTON RLRL: Diseases of the Skin, 10th ed. The C. V. Mosby Co., St. Louis, 1939. Google Scholar13. GUBNER R: Effect of aminopterin on epithelial tissues. Arch. Derm. (Chicago) 64: 688, 1951. CrossrefGoogle Scholar14. REESBENNETTBOSTICK RBJHWL: Aminopterin for psoriasis. Arch. Derm. (Chicago) 72: 133, 1955. CrossrefGoogle Scholar15. EDMUNDSONGUY WFWB: Treatment of psoriasis with folic acid antagonists. Arch. Derm. (Chicago) 78: 200, 1958. CrossrefGoogle Scholar16. REESBENNETT RBJH: Methotrexate vs. aminopterin for psoriasis. Arch. Derm. (Chicago) 83: 970, 1961. CrossrefMedlineGoogle Scholar17. VAN SCOTTAUERBACHWEINSTEIN EJRGD: Parenteral methotrexate in psoriasis. Arch. Derm. (Chicago) 89: 550, 1964. CrossrefMedlineGoogle Scholar18. VAN SCOTTREINERTSON EJRP: Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J. Invest. Derm. 33: 357, 1959. CrossrefMedlineGoogle Scholar19. ROTHBERGCROUSELEE SRGJL: Glycine-C-14 incorporation into the proteins of normal stratum corneum and the abnormal stratum corneum of psoriasis. J. Invest. Derm. 37: 497, 1961. CrossrefMedlineGoogle Scholar20. VAN SCOTTEKEL EJTM: Kinetics of hyperplasia in psoriasis. Arch. Derm. (Chicago) 88: 373, 1963. CrossrefMedlineGoogle Scholar21. BLOCKEDGCOMBEISENVAN SCOTT JBJAEJ: Mycosis fungoides: natural history and aspects of its relationship to other malignant lymphomas. Amer. J. Med. 34: 228, 1963. CrossrefMedlineGoogle Scholar22. CLENDENNINGBRECHERVAN SCOTT WEGEJ: Mycosis fungoides: relationship to malignant cutaneous reticulosis and the Sézary syndrome. Arch. Derm. (Chicago) 89: 785, 1964. CrossrefMedlineGoogle Scholar23. WRIGHTGUMPORTGOLOMB JCSLFM: Remissions produced with the use of Methotrexate in patients with mycosis fungoides. Cancer Chemother. Rep. 9: 11, 1960. MedlineGoogle Scholar24. ZARUBAKUTAELLIS FAJ: Treatment of mycoses fungoides with 6-azauracilriboside. Lancet 1: 275, 1963. CrossrefMedlineGoogle Scholar25. FINKKOUTRASCALABRESI MEGAP: Vinblastine (VLB) therapy of Hodgkin's disease and related disorders. Clin. Res. 9: 332, 1961. Google Scholar26. BRENNANVAITKEVICIUSREBUCK MJVKJW: Megaloblastoid anemia of the induced "thymine-less" state (observations during 5-fluorouracil treatment). Blood 15: 422, 1960. Google Scholar27. TALLEYVAITKEVICIUS RWVK: Megaloblastosis produced by a cytosine antagonist 1-β-D-arabinofuranosylcystosine. Blood 21: 352, 1963. CrossrefMedlineGoogle Scholar28. BERLINRALLMEADFREIREICHVAN SCOTTHERTZLIPSETT NIDJAEJERMB: Folic acid antagonists. Effects on the cell and the patient. Ann. Intern. Med. 59: 931, 1963. LinkGoogle Scholar29. HUGULEYBAINRIVERSCOGGINS CMJASR: Refractory megaloblastic anemia associated with excretion of orotic acid. Blood 14: 615, 1959. CrossrefMedlineGoogle Scholar30. SMITH LH: Hereditary orotic aciduria—pyrimidine auxotrophism in man. Amer. J. Med. 38: 1, 1965. CrossrefMedlineGoogle Scholar31. SMITHSULLIVANHUGULEY LHMCM: Pyrimidine metabolism in man. IV. The enzymatic defect of orotic aciduria. J. Clin. Invest. 40: 656, 1961. CrossrefMedlineGoogle Scholar32. FALLONLOTZSMITH HJMLH: Congenital orotic aciduria: demonstration of an enzyme defect in leukocytes and comparison with drug-induced orotic aciduria. Blood 20: 700, 1962. CrossrefGoogle Scholar33. HUGULEY CM: Personal communication. Google Scholar34. WINTROBE MM: Clinical Hematology, 5th ed. Lea & Febiger, Philadelphia, 1961. Google Scholar35. RUBINWEISBERGERBOTTISTORAASLI DASREJP: Changes in iron metabolism in early chloramphenicol toxicity. J. Clin. Invest. 37: 1286, 1958. CrossrefMedlineGoogle Scholar36. O'ROURKEECKERT RAGE: Methotrexate-induced hepatic injury in an adult. Arch. Intern. Med. (Chicago) 113: 191, 1964. CrossrefMedlineGoogle Scholar37. MCILVANIEMACCARTHY SJJD: Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 14: 80, 1959. CrossrefMedlineGoogle Scholar38. CLARKHSIAHUNTSMAN PAYERG: Toxic complications of treatment with 6-mercaptopurine; two cases with hepatic necrosis and intestinal ulceration. Brit. Med. J. 1: 393, 1960. CrossrefMedlineGoogle Scholar39. FALLONFREIBLOCKSEEGMILLER HJEJJE: The uricosuria and orotic aciduria induced by 6-azauridine. J. Clin. Invest. 40: 1906, 1961. CrossrefMedlineGoogle Scholar40. FALLONFREIFREIREICH HEEJ: Correlations of the biochemical and clinical effects of 6-azauridine in patients with leukemia. Amer. J. Med. 33: 526, 1962. CrossrefGoogle Scholar41. WALTONBLOCKHEYDE RWDJ: A comparative study of uric acid values of whole blood in patients with psoriasis and other dermatoses. J. Invest. Derm. 37: 125, 1961. CrossrefMedlineGoogle Scholar42. STEINBERGBECKERFITZPATRICKKIERLAND AGSWTBRR: A genetic and statistical study of psoriasis. Amer. J. Hum. Genet. 3: 267, 1951. MedlineGoogle Scholar43. HITCHINGS GH: Summary of informal discussion on the role of purine antagonists. Cancer Res. 23: 1218, 1963. MedlineGoogle Scholar44. RUNDLESWYNGAARDENHITCHINGSELLIONSILBERMAN RWJBGHGBHR: Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia, and gout. Trans. Ass. Amer. Physicians 76: 126, 1963. Google Scholar45. DECONTITURNERCALABRESI RCRWP: Beneficial effects of azauridine in polycythemia vera with control of hyperuricemia by hydroxypyrazolopyrimidine. Proc. Amer. Ass. Cancer Res. 6: 14, 1965. Google Scholar46. CALABRESIMEYER POO: Polycythemia vera. I. Clinical and laboratory manifestations. Ann. Intern. Med. 50: 1182, 1959. LinkGoogle Scholar47. ELVESBUTTOOISRAELSWILKINSON MWASMCJF: Chromosome changes caused by 6-azauridine during treatment of acute myeloblastic leukaemia. Brit. Med. J. 1: 156, 1963. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PAUL CALABRESI, M.D.; RAYMOND W. TURNER, M.D.Affiliations: New Haven, ConnecticutFrom the Departments of Medicine and Pharmacology, Yale University School of Medicine, New Haven, Conn.This work was supported in part by grants OG-14, CA-05944, CA-5138, U. S. Public Health Service, Bethesda, Md., and grants from the Burroughs Wellcome Foundation and the Olsen Memorial Fund.Dr. Calabresi is a Burroughs Wellcome Scholar in clinical pharmacology, and Dr. Turner is a U. S. Public Health Service Special Research Fellow supported by grant IF 3-AM-24,279-01.Requests for reprints should be addressed to Paul Calabresi, M.D., Department of Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, Conn. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPharmacological Differences, Qualitative and Quantitative, Between Man and Other SpeciesHistory of treatmentsL'auto-immunité: un concept générateur d'outils thérapeutiquesINVESTIGATIONAL AGENTS FOR RHEUMATOID ARTHRITISTreatment of psoriatic arthropathyAzarbine-homocystinemia-thrombosis in historical perspectiveCytotoxic agents for use in dermatology. IAzapyrimidine nucleosides: metabolism and inhibitory mechanismsDecrease of serum pyridoxal phosphate levels and homocystinemia after administration of 6-azauridine triacetate and their prevention by administration of pyridoxineThe uses of systemic chemotherapeutic agents in psoriasisDrug-induced Megaloblastic ChangeEffect of 6-azauracil, and of certain structurally similar compounds, on three pyridoxal-phosphate requiring enzymes involved in neurotransmitter metabolismAnomalous nucleosides and related compoundsAzaribine (triacetyl-6-azauridine) in psoriasisTreatment of psoriatic arthritis with azaribineMANAGEMENT OF Rh ISOIMMUNISATIONTHROMBOSIS AND PSORIASISATTITUDES TO CHILDREN'S ACCIDENTSTreatment Of Psoriasis With Oral Mycophenolic AcidNUCLEOSIDE ANALOGS IN THE TREATMENT OF NONNEOPLASTIC DISEASESBASIS FOR CLINICAL RESISTANCE TO ANTITUMOR NUCLEOSIDE ANALOGSDouble-blind controlled crossover high-dose study of Azaribine in psoriasis*Azapyrimidine NucleosidesLow dose azaribine in the treatment of psoriasisImmunosuppressive AgentsAlterations in metabolism of copper and zinc after administration of 6-azauridine triacetateProblems in Predicting Drug Effects across Species LinesAntibody response in psoriatic patients treated with 6-azauridine-triacetateChanges in serum and urine amino acids in patients with progressive systemic sclerosis treated with 6-azauridine triacetateTreatment of psoriatic arthritis with 6-mercaptopurineThe Present Status of Chemotherapy in DermatologyNew indications for 6-azauridine treatment in man. A reviewANTIMETABOLITES AND PSORIASISHyperaminoacidemia in rabbits treated with 6-azauridine triacetateTime-response curves in the evaluation of the clinical efficacy of drugsTeratogenic effect of 6-azauridine in ratsA Double-Blind Study of Azaribine in the Treatment of PsoriasisWILLIAM R. VOGLER, M.D., SIDNEY OLANSKY, M.D., F.A.C.P.Treatment of Polycythemia Vera with Azauridine and AzaribineRONALD C. DECONTI, M.D., PAUL CALABRESI, M.D.Abortifacient and teratogenic effects of triacetyl-6-azauridine in the monkeyTherapeutic effects of 6-azauridine-triacetate in psoriasisCHROMOSOMES IN JUVENILE BREAST CANCERPARENTERAL METHOTREXATE FOR PSORIASISMegaloblastic Anemia Possibly Induced by Triamterene in Patients with Alcoholic Cirrhosis Two Case ReportsFRED L. LIEBERMAN, M.D., JOSEPH R. BATEMAN, M.D.Triacetyl 6-Azauridine in Mycosis FungoidesPYRIMIDINE METABOLISM AS A TARGET FOR CHEMOTHERAPYCutaneous Manifestations of the Leukemia-Lymphoma GroupChemical Suppression of Adaptive Immunity 1 February 1966Volume 64, Issue 2Page: 352-371KeywordsBiosynthesisClinical pharmacologyDermatologyLesionsMedical servicesNucleic acidsPharmacologyPsoriasisToxicityUlcers ePublished: 1 December 2008 Issue Published: 1 February 1966 PDF downloadLoading ...